Please ensure Javascript is enabled for purposes of website accessibility
Brenton Flynn

Brenton Flynn


Recent articles

Pull Quote


Should You Buy Abbott Labs Today?

Is Abbott Labs a buy today? Here are a few reasons to consider.

Why Sell Abbott Labs? Here Are 3 Reasons to Consider

Holding a position in Abbott Labs? Here are a few reasons to consider selling.

What Should Investors Watch With AbbVie?

The key factors every investor in this blockbuster pharmaceutical company needs to know.

What Are the Opportunities Ahead for Abbott Labs Investors?

Thinking of buying Abbott Labs? Here are some opportunities with this stock you should know about.

What Are the Risks With AbbVie?

The biggest risks AbbVie investors need to be aware of.

What Are the Risks for Abbott Labs Investors?

Holding a position in Abbott Labs? You need to know the risks.

3 Reasons to Buy AbbVie Today

Why you should consider buying this pharmaceuticals player and its powerhouse drug today.

Why Apple, Like Tiger Woods, Will Return to Greatness

On Monday, Tiger Woods won the Arnold Palmer Invitational at Bay Hill Country Club to regain his status as the world's No. 1 professional golfer. But what on earth do Tiger Wood and Apple have in common?

Intuitive Surgical's March Madness

The bearish sentiment around Intuitive Surgical won't go away anytime soon, so new investors should be prepared to deal with some volatility over the short term.

Forget Obamacare -- Apple's iPhone Could Help Save Health Care

The jury's still out on whether Obamacare can truly stem the rise in health care costs. However, technology based on Apple's iPhone and other smartphones could be a key tool for saving the system money while helping patients and investors.

Obamacare vs. Arkansas: The Great Health Insurance Debate

Arkansas is trying to expand Medicaid in a way that could transform the way states approach Obamacare's Medicaid health insurance expansion. What does this mean for health insurance companies?

Why the Health Care Arms Race Hurts This Stock

Being a middle man isn't fun when you're being pressured by increasingly large customers. The same is true in health care, where one distributor is being hurt by industry consolidation, some of it instigated by Obamacare.

The Future of AstraZeneca, Pharma's Biggest Dividend

Ahead of its investor meeting, AstraZeneca outlined some key strategic priorities meant to revive the flailing big pharma company.

Don't Believe This Obamacare Cost Projection

Before trusting a forecast, make sure you understand the motivations of the people behind the predictions. In the case of a new forecast related to Obamacare's Medicaid expansion, one analyst has his doubts.

Does Merck's Dividend Have Room to Soar?

With its top drug's patent loss hurting sales, and setbacks in the clinic slowing new drugs to market, is Merck's dividend on solid footing?

Does St. Jude Medical Have a Rock-Solid Dividend?

Can you really rely on St. Jude Medical for its dividend?

Does UnitedHealth Group Have a Rock-Solid Dividend?

With Obamacare's most onerous provisions going into effect soon for health insurers, does UnitedHealth Group have a dividend you can really rely on?

Does Quality Systems Have a Rock-Solid Dividend?

Doctors and hospital systems are flocking toward electronic health records, but is Quality Systems and its dividend benefiting from the movement?

Does Medtronic Have a Rock-Solid Dividend?

Medtronic has experienced weakness in some of its core markets recently, so is its dividend still rock-solid?